Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141425 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02141425: Completed Phase 1 study, sponsored by Astellas Pharma Global Development.
NCT02141425 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02141425, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single ascending doses of ASP015K.
Interventions
- DRUG Placebo
- DRUG ASP015K
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
What the finished NCT02141425 record still lists
NCT02141425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02141425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02141425 about?
NCT02141425 is a clinical study titled "A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects". The purpose of this study is to assess the safety, tolerability and pharmacokinetics of single ascending doses of ASP015K.
What is the current status of trial NCT02141425?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-03. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02141425?
The interventions under investigation include: Placebo (DRUG), ASP015K (DRUG).
Who is sponsoring clinical trial NCT02141425?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02141425's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia